Details for New Drug Application (NDA): 207124
✉ Email this page to a colleague
The generic ingredient in DEFERASIROX is deferasirox. There are twenty drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the deferasirox profile page.
Summary for 207124
Tradename: | DEFERASIROX |
Applicant: | Teva Pharms Usa |
Ingredient: | deferasirox |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, FOR SUSPENSION;ORAL | Strength | 125MG | ||||
Approval Date: | Sep 23, 2022 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, FOR SUSPENSION;ORAL | Strength | 250MG | ||||
Approval Date: | Sep 23, 2022 | TE: | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, FOR SUSPENSION;ORAL | Strength | 500MG | ||||
Approval Date: | Sep 23, 2022 | TE: | RLD: | No |
Complete Access Available with Subscription